Please complete the following form to subscribe to our news service.

Name :
Company :
Email Address :
City :
State :
Zip :
Phone Number :
Comments :

Press Releases

Media Kits

Media Inquiries


Viral Genetics, Inc. (OTC BB:VRAL.OB - News) previously stated its expectation that the results of the Phase III human clinical trial conducted in South Africa would be available by today. While this expectation will not be met today, Viral Genetics expects no significant delay in the release of the results of the clinical trial conducted in South Africa.

The "TNP-001 Study" was a Phase III, double-blind, placebo-controlled, randomized, multi-center study of 137 HIV positive patients treated with either VGV-1 or placebo that began enrollment in August 2004 and completed follow up in November 2005.

About Viral Genetics, Inc.
Viral Genetics, Inc. is a drug discovery and development company based in southern California developing treatments for infectious disease, autoimmune disease and immunological deficiency through its patented Thymus Nuclear Protein technology.

Click here for more.


Home | About Us | Our Team | Scientific Advisory Board | Discovery
Vision | Immune-Based Therapies | TNP | Development | VGV-1
History | Product Timeline | Clinical Trials
Press Releases | Media Kits | Media Inquiries | News Subscription Service
Investor Contacts | Email Alerts | Fact Sheet | Contact Us | SEC Filings
Glossary | Stock Information | Corporate Governance & Board of Directors
University of Colorado License | Careers